Syndesis Health
NEW YORK, NY / ACCESSWIRE / May 11, 2023 / Syndesis Health announced today that it has signed a research collaboration and information sharing agreement with Fundación Cardio Infantil Instituto de Cardiología (LaCardio), a leading cardiovascular hospital in Bogotá, Colombia.
LaCardio is joining the Syndesis Health Network alongside progressive healthcare institutions from South America, Asia, and Africa. Syndesis Health created its global network of healthcare partners to enable secure access to a multi-country, real-world data set. Syndesis Health's global research platform, Syntium, unifies de-identified clinical data from these healthcare partners in a secure, ethical, and compliant manner for the improvement of global health outcomes.
The partnership enables LaCardio to extend its commitment to improving patient outcomes by leveraging the Syndesis Health platform for access to data, analytics, and other technical resources. In addition, the partnership enables the hospital to engage in collaborative research opportunities with peer institutions around the world that are a part of the network.
Hans Godfrey, COO and head of Latin America data partnerships for Syndesis Health, commented: "We believe that the future of healthcare will be data-driven. With LaCardio as a partner in the Syndesis Health Network, we will together expand the potential for real-world data to enable research and treatments in the cardiovascular space."
Dr. Juan Gabriel Cendales, Executive Director of LaCardio, stated: "One of the strategic priorities of LaCardio as a university hospital and scientific research center is to continue advancing in scientific studies while contributing to the health of the people in Colombia and the region. Having valuable data, evaluating, and applying tools, such as AI, in healthcare allows us to anticipate the needs of the population, evaluate new alternatives and improve the experience of patients and collaborators. This alliance is part of the path in which we are working to be the hospital of the future."
About Syndesis Health
Syndesis Health accelerates research and innovation for healthcare and life sciences companies. The company was founded on the potential for real-world clinical data to advance medical research, improve patient health outcomes, and inform healthcare policy decisions. The Syndesis Health Network enables secure collaboration amongst member organizations and is powered by Syntium, the Syndesis data platform. Visit our website at https://syndesis.com to learn more.
About LaCardio
Fundación Cardioinfantil-LaCardio is a private, nonprofit institution with 50 years of experience. Founded in 1973 by brothers Reinaldo and Camilo Cabrera Polanía, it is one of the few Colombian institutions accredited by the Joint Commission International and has national accreditation granted by ICONTEC. Since 2015, LaCardio is recognized as a University Hospital by the Intersectoral Committee for Human Talent in Health, in compliance of the Ministries of Health and Education of Colombia. Its commitment to health transcends through its mission: to operate on low-income children with heart problems. The MERCO 2022 ranking positioned LaCardio as the best hospital in Colombia. In 2021, Americaeconomia ranked LaCardio 5th in Latin America, evaluating key processes and indicators, including patient safety & dignity, human capital, capacity, and knowledge management.
Contact Information
Leah Patterson
Chief Marketing Officer
leah.patterson@syndesis.com
+1.646.274.1420
Liliana Milena Toro Sánchez Sánchez
Marketing & Communications
lmtoro@lacardio.org
+3157288712
SOURCE: Syndesis Health
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/754175/Syndesis-Health-LaCardio-Sign-Research-Collaboration-Agreement
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Innodata to Report Third Quarter 2025 Results16.10.2025 14:30:00 CEST | Press release
NEW YORK, NY, AL / ACCESS Newswire / October 16, 2025 / INNODATA INC. (Nasdaq:INOD) today announced that it will report Third Quarter 2025 results after the market closes on Thursday, November 6, 2025. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com. Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day. The call-in numbers for the conference call are: (+1) 800 549 8228 North America (+44) 800 279 7040 United Kingdom (+1) 289 819 1520 International Participant Access Code 42719 # Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of Innodata's website at https://investor.innodata.com/events-and-presentations/. Please note that the Webcast feature will be in listen-only mode. Call-in replay will be available for seven days following the conference call, and Webcast replay will be available for 30 days following the c
Karbon-X Corp. Reports Q1 2026 Revenue Growth and Strengthened Financial Position16.10.2025 14:00:00 CEST | Press release
Revenue reached $35.7 million, marking a 27,883% year-over-year increase driven by accelerated trading activity, and the continued expansion of Karbon-X's global carbon operations. CALGARY, AB / ACCESS Newswire / October 16, 2025 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or "the Company"), a vertically integrated climate solutions company, today announced financial results for the first quarter ended August 31, 2025, marking record revenue growth and continued execution of its strategic plan. The full filing is available under the Company's profile on OTC Markets at www.otcmarkets.com/stock/KARX/overview Karbon-X's Q1 2026 results underscore its accelerating growth trajectory and strong execution across all areas of its business. Q1 2026 Highlights Revenue Growth Karbon-X delivered transformational top-line growth as its carbon trading operations scaled globally. Revenue reached $35.7 million, up 27,883% year-over-year compared to $127,429 in Q1 2025. Growth was driven by the successfu
RelyEZ Unveils VentureEdge 800: Next-Generation 800 V AC Energy Storage System Tailored for Europe16.10.2025 08:20:00 CEST | Press release
BRUSSELS, BE / ACCESS Newswire / October 16, 2025 / RelyEZ Energy Storage proudly announces the launch of its latest innovation, VentureEdge 800, a next-generation 800 V AC battery energy storage system (BESS) designed to meet Europe's evolving grid requirements. The launch coincides with RelyEZ's participation as a Gold Sponsor at the Energy Storage Global Conference (ESGC 2025) in Brussels, underscoring its commitment to supporting the region's clean energy transition with cutting-edge, bankable storage technologies. A New Standard for European Grid Compatibility Across Europe, most PV and wind installations operate on 0.8 kV/15 kV transformer infrastructure, while conventional 0.4 kV PCS systems require additional step-up transformers - increasing cost, space, and energy loss. VentureEdge 800 eliminates this layer entirely, offering direct 800 V AC connectivity for seamless integration with existing assets. This forward-looking design translates into: 5-15 % CAPEX savings through re
Owkin Launches K Pro: The First Agentic AI Co-Pilot for Biopharma Powered by Biological Reasoning Models16.10.2025 07:00:00 CEST | Press release
Enterprise platform, queried through natural language, to help pharma, biotech, and investors make better decisions. High-quality biological patient data, enriched and integrated for use by AI agents. PARIS, FRANCE, GB / ACCESS Newswire / October 16, 2025 / Owkin today announces the launch of K Pro, its co-pilot bringing advanced agentic AI to biomedical research and drug development. K Pro helps pharmaceutical companies and biotechs make smarter decisions across the discovery and development pipeline, increase clinical success rates, and deliver decision-grade, data-driven biological insights fast enough to change program trajectories.Owkin K Pro Owkin K Pro - the Agentic AI Co-Pilot for Biopharma Built on a decade of Owkin's AI innovation and in close collaboration with leading academic and industry partners, K Pro is a scientist-first co-pilot, accessible to both researchers and executives. Through natural language interaction, users can ask complex biological questions and receive
Compliance Couture: How SMX and CETI are Changing the Rules for Fashion Sustainability (NASDAQ: SMX)15.10.2025 19:10:00 CEST | Press release
NEW YORK, NY, NY / ACCESS Newswire / October 15, 2025 / Global fashion brands require a single, essential ingredient to thrive: trust. Trust that its product is genuine, trust that the craftsmanship is authentic, and trust that the values behind the brand align with the ones it promotes. From Paris ateliers to fast-fashion retailers, every label's reputation depends on that same promise of quality, consistency, and credibility. But the world has changed. Supply chains have gone global. Sustainability has become a shareholder demand. And the old way of proving trust - through reputation alone - no longer cuts it. Today, trust must be earned through evidence. That's where SMX (NASDAQ:SMX) and CETI, the European Center for Innovative Textiles, come in. Together, they've created something fashion has needed for years: proof. Their industrial-scale collaboration embeds molecular-level traceability directly into textile fibers, giving every material its own unbreakable digital fingerprint. I
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom